

Maya H Buch



Country: UK

Contact e-mail: m.buch@leeds.ac.uk

Year of birth: 1972

Main diplomas:

- MD: 1995, UK
- MRCP: 1998, UK
- PhD: 2007, University of Leeds, UK
- Rheumatologist: 2009, UK

Current position and hospital/university:

Senior Lecturer & Honorary Consultant Rheumatologist; University of Leeds, UK

Position within EULAR/international experience:

- EMEUNET Steering Committee member
- EMEUNET Education sub-group lead
- University of Michigan, USA; 2005-2006

Role as EMEUNET working group member: Steering group role, lead in education activities

Areas of Research/Interest: Immunotherapies/biologics and inflammatory arthritis, investigating response and identifying sub-groups responsive to specific targeted therapy; Systemic sclerosis

Keywords: Rheumatoid arthritis, biologic therapy, treatment response, clinical trials

Selected Publications:

- Buch MH, Reece R, Quinn MA, et al. The Value of Synovial Cytokine Expression in predicting the clinical response to anti-TNF therapy (Infliximab). *Rheumatology* 2008 Oct; 47(10): 1469-75
- Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed TNF blockade: a histological, gene expression and dynamic MRI study. *Ann Rheum Dis* 2009; 68(7):1220-7
- Nam JL, Winthrop KL,, Buch MH. Current evidence for the management of rheumatoid arthritis with biological disease-modifying anti-rheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. *Ann Rheum Dis* 2010; 69(6):976-86.
- Buch MH, Smolen JS, Betteridge N, et al; for the Rituximab Consensus Expert Committee. Updated Consensus Statement on the use of rituximab in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2011; 70(6):909-920
- Buch MH, Aletaha D, Emery P, et al. Reporting of long-term extension studies: lack of consistency calls for consensus. *Ann Rheum Dis*. 2011;70(6):886-90

Date of last update of the CV: November 2011